Blood cancers

Novel STAMP inhibitor potentially practice changing in CML

The novel agent asciminib out-performed bosutinib in a phase III trial of patients with heavily pretreated chronic phase chronic myeloid leukaemia (CML), according to results presented at the ASH 2020 meeting. Asciminib is a first-in-class STAMP inhibitor that specifically targets the ABL myristoyl pocket. This differs from all approved tyrosine kinase inhibitors, which bind to ...

Already a member?

Login to keep reading.

© 2021 the limbic